MeiraGTx Q3 2026: Misses Matter Less Than the BLA Clock

MeiraGTx posted a loss of $0.53 per share in the third quarter of 2026, missing expectations. Revenue of $4.8 million also came in below estimates, though it was up sharply year over year as the company collected contract manufacturing and transition services fees from Lilly and Reogen following the reacquisition of bota-vec from Janssen in May 2026.

The headline shortfalls trace directly to a surge in pre-commercial spending. R&D expense climbed to $39.3 million in the quarter, driven by bota-vec regulatory preparation, AQUAx2 clinical activity, and AAV-GAD batch costs. That spending is intentional: CEO Alexandria Forbes noted in the filing that the MAA dossier for the EMA is complete and awaiting submission, with the FDA BLA expected to follow in the first quarter of 2027.

MeiraGTx is building toward what it calls a late-2027 commercial launch of bota-vec, a gene therapy targeting XLRP, a rare inherited retinal disease for which no approved treatments currently exist. The company estimates more than 20,000 XLRP patients in the U.S. and EU combined, and bota-vec carries FDA Fast Track and orphan drug designation, as well as EU PRIME and ATMP classification, advantages that shorten the path to approval.

The balance sheet softens the near-term concern. Cash stood at $184.7 million at quarter end, and a $95 million upfront payment from Hologen is expected to fund operations into the second half of 2028. That runway covers the two critical regulatory submissions and the mid-2027 readout from the pivotal Phase 2 AQUAx2 study for AAV2-hAQP1 in radiation-induced dry mouth, which carries FDA Breakthrough Therapy Designation.

One line item worth noting in the EPS figure: results included a $3.9 million loss on the Reogen equity-method investment, partially offset by a $1.6 million gain from fair-value changes on royalty notes and $0.4 million in derivative-related other income. Strip those items out and the underlying operating trajectory looks consistent with the company's pre-launch spending posture.

For investors, the EMA submission date in December 2026 and the FDA BLA filing in early 2027 are the events that will move this stock. A quarterly earnings miss during a known period of heavy pipeline investment is largely noise against that backdrop; the real scorecard is whether those regulatory filings arrive on schedule.